Literature DB >> 9409190

Eight-year experience of malignant lymphoma--survival and prognostic factors.

J S Hahn1, S Lee, S Y Chong, Y H Min, Y W Ko.   

Abstract

Several reports have suggested a geographic difference in the histopathologic characteristics and prognosis of malignant lymphoma around the world. We tried to evaluate the clinical and histopathologic characteristics, therapeutic outcomes, and prognostic features of malignant lymphoma, particularly in Korean patients. Three hundred and seventy-six adult patients with the initial histopathologic diagnosis of malignant lymphoma of Yonsei University College of Medicine over an 8-year period were analyzed, retrospectively, with the following results: 1) There were 47 cases of Hodgkin's disease (HD) (12.5%) and 329 of non-Hodgkin's lymphoma (NHL) (87.5%) with a 1:7 ratio. The most common histopathologic subtype of HD was mixed cellularity (44.7%), and that of NHL was intermediate grade (70.8%), especially diffuse large-cell type (44.1%), whereas follicular type was less common. In regard to the incidence of extranodal presentation, it is rare in HD (4.2%), but occurs in 49.8% of patients with NHL. 2) The complete remission (CR) rate was 91.5% in HD and 63.6% in NHL, and the 5-year and 7-year disease-free survival rates were 71.3% and 57.0% in HD; 67.0% and 49.6% in NHL. The 5-year and 8-year overall survival rates were 90.7% and 68.0% in HD; 65.2% and 60.2% in NHL. 3) By multivariate analysis, we found that age, performance status, histopathologic grade, stage, serum lactate dehydrogenase (LDH) and beta 2-microglobulin were the useful prognostic factors in predicting survival in NHL, while no definite prognostic factors were found in HD. Also, in NHL patients less than 60 years old, stage, serum LDH, and histopathologic grade were closely associated with their therapeutic outcomes. In conclusion, the characteristics of malignant lymphoma in our hospital differ from those in Western countries with respect to the clinical, histopathologic and immunophenotypic patterns, but the prognostic factors and overall therapeutic outcomes were quite comparable to those of other reports from Western countries.

Entities:  

Mesh:

Year:  1997        PMID: 9409190     DOI: 10.3349/ymj.1997.38.5.270

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  10 in total

1.  Therapeutic comparison of chemotherapy and surgery for early stage diffuse large B-cell gastric lymphoma.

Authors:  Soo-Jeong Kim; June-Won Cheong; Jee Sook Hahn
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

2.  Treatment of Hodgkin's disease: a twenty-year follow-up of patients at a center in Korea.

Authors:  June-Won Cheong; Soo Young Park; Jae Kyung Roh; Chang Ok Suh; Jee Sook Hahn
Journal:  Yonsei Med J       Date:  2006-08-31       Impact factor: 2.759

3.  Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.

Authors:  Changhoon Yoo; Shin Kim; Byeong Seok Sohn; Jeong-Eun Kim; Dok Hyun Yoon; Jooryung Huh; Dae Ho Lee; Sang-We Kim; Jung-Shin Lee; Cheolwon Suh
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 2.884

4.  Three cases of diffuse large B-cell lymphoma presenting as primary splenic lymphoma.

Authors:  Ja Kyung Kim; Jee Sook Hahn; Gwi Eon Kim; Woo-Ick Yang
Journal:  Yonsei Med J       Date:  2005-10-31       Impact factor: 2.759

5.  High dose chemotherapy and autologous stem cell transplantation in non-Hodgkin's lymphoma: an eight-year experience.

Authors:  Hyun Chang; June-Won Cheong; Jee-Sook Hahn
Journal:  Yonsei Med J       Date:  2006-10-31       Impact factor: 2.759

6.  Nine-year survival of lymphoblastic lymphoma patients.

Authors:  Wonseok Kang; Jee Sook Hahn; Jin Seok Kim; June-Won Cheong; Woo Ik Yang
Journal:  Yonsei Med J       Date:  2006-08-31       Impact factor: 2.759

7.  Primary lymphoma of bone--survival and prognosis.

Authors:  Jun Yong Choi; Jee Sook Hahn; Chang Ok Suh; Woo Ick Yang
Journal:  Korean J Intern Med       Date:  2002-09       Impact factor: 2.884

Review 8.  Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor.

Authors:  Changhoon Yoo; Dok Hyun Yoon; Cheolwon Suh
Journal:  Blood Res       Date:  2014-09-25

9.  Primary splenic lymphoma: Current diagnostic trends.

Authors:  Sachin B Ingle; Chitra R Hinge Ingle
Journal:  World J Clin Cases       Date:  2016-12-16       Impact factor: 1.337

10.  SUVmax/THKmax as a biomarker for distinguishing advanced gastric carcinoma from primary gastric lymphoma.

Authors:  Liping Fu; Hongming Li; Hui Wang; Baixuan Xu; Yong Fan; Jiahe Tian
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.